(Q46800406)

English

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes (English)

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D J Betteridge

1

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

B Vergès

2

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

publication date

10 November 2005

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

48

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

12

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

2477-2481

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

https://scigraph.springernature.com/pub.10.1007/s00125-005-0034-1

0 references

Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0034-1

21 January 2018

Is sulphonylurea therapy effective long term? A 3-year study with gliclazide.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-005-0034-1

21 January 2018

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dyslipidemia management in adults with diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16283239

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-005-0034-1

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

release_gwcnbrardrbzppils7clpxt5zm

1 reference

https://api.fatcat.wiki/v0/release/gwcnbrardrbzppils7clpxt5zm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

25 December 2017

http://europepmc.org/abstract/MED/16283239

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46800406&oldid=2132764138"